The real promise of genomics research. Genomics collaboration event material
The real promise of genomics research has only recently become apparent as a result of the huge decline in the cost of genome sequencing, large public sector and pharmaceutical investment and a commitment to explore changes in the way healthcare is delivered. It promises to change patients' lives and increase life expectancy in an increasingly challenging global economy.
In the UK the Department of Health has established a company, Genomics England, to deliver the 100,000 Genomes Project, currently the largest national sequencing project of its kind in the world.
An event to explore collaboration opportunities between UK and Finland was hosted by the Ambassador of Finland and arranged by Team Finland in collaboration with Finpro and Helsinki Business Hub on the 3rd November, at the Finnish Residence in London.
The event facilitated discussion on both the national project and at regional clinical partnership level to establish the progress that has been made and where any commercial opportunities lie. The aim is to enhance the collaboration and investment opportunities between Finland and the UK within the scope of Genomics and the development of gene-targeted medicine.
The interesting event material has now been published and can be found here.
Introduction, Paul Cornes
Finnish Biobanks as enablers Professor Olli Carpen, Professor of Pathology, Scientific Director, University of Helsinki & Helsinki Biobank
Genomics England - Update on 100,000 Genomes Project, including the business & research collaboration opportunities. Professor Mark Caulfield FMedSci – Chief Scientist, Board Member Genomic England
Post Meeting Report Genomics collaboration